NT-pro BNP:A new diagnostic screening tool for Kawasaki disease

Purpose:The purpose of this study was to determine whether N-terminal fragment of B-type natriuretic peptide(NT-proBNP) may be used to differentiate acute Kawasaki disease(KD) from other clinically similar diseases. Methods:Using electrochemiluminescence immunoassay, NT-proBNP concentrations were measured in the acute phase within 10 days after the onset of KD(n=58) and in the convalescent phase, 60 to 81 days after the onset(n=51), and also in patients with acute febrile disease as a control(n=34). Echocardiography was performed to detect pericardial effusion(PE) and coronary artery lesions(CAL), and to measure the left ventricular dimension at diastole(LVIDd) and ejection fraction(LVEF). The cutoff value of NT-proBNP for separating KD from other diseases was determined. Results:NT-proBNP concentration in the acute phases of KD was significantly higher than that in the control group(1,501.6±2,132.6 vs. 139.0±88.8 pg/mL, P260 pg/mL may be highly suggestive of acute KD. NT- proBNP may be used as a diagnostic tool for KD.

[1]  Arthur J. Moss,et al.  Moss and Adams' heart disease in infants, children, and adolescents : including the fetus and young adult , 2016 .

[2]  A. Korach,et al.  N‐terminal pro‐B‐type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases , 2004, Acta paediatrica.

[3]  A. D. de Bold,et al.  Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. , 2004, Journal of molecular and cellular cardiology.

[4]  C. Hall.  Essential biochemistry and physiology of (NT‐pro)BNP , 2004, European journal of heart failure.

[5]  E. Erdmann,et al.  Use of NT‐proBNP in routine testing and comparison to BNP , 2004, European journal of heart failure.

[6]  M. Nieminen,et al.  Clinical applications of B-type natriuretic peptide (BNP) testing. , 2003, European heart journal.

[7]  M. Rauh,et al.  Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. , 2003, Clinical chemistry.

[8]  M. Drazner,et al.  B-type natriuretic peptide in cardiovascular disease , 2003, The Lancet.

[9]  Roberto Cardarelli,et al.  B-type natriuretic peptide: a review of its diagnostic, prognostic, and therapeutic monitoring value in heart failure for primary care physicians. , 2003, The Journal of the American Board of Family Practice.

[10]  M. Cowie,et al.  BNP and congestive heart failure , 2003 .

[11]  T. Mir,et al.  Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. , 2002, Pediatrics.

[12]  R. Pitetti,et al.  Myocardial infarction and atypical Kawasaki disease in a 3-month-old infant , 2002, Pediatric emergency care.

[13]  A. Rowley.  Incomplete (atypical) Kawasaki disease. , 2002, The Pediatric infectious disease journal.

[14]  T. Kawamura,et al.  Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease , 2002, Cardiology in the Young.

[15]  P. Hildebrandt,et al.  Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations , 2001, European journal of heart failure.

[16]  H. Kawaguchi,et al.  Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease , 2000, Pediatrics international : official journal of the Japan Pediatric Society.

[17]  K. Nakao,et al.  Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. , 1999, Journal of molecular and cellular cardiology.

[18]  R. Bonow,et al.  New insights into the cardiac natriuretic peptides. , 1996, Circulation.

[19]  K. Hirayama,et al.  Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-α and interleukin-1β by peripheral blood monocytes in the acute phase of Kawasaki disease , 1996, European Journal of Pediatrics.

[20]  A. Richards,et al.  The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. , 1995, Biochemical and biophysical research communications.

[21]  K. Nakao,et al.  Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. , 1995, The Journal of clinical investigation.

[22]  K. Nakao,et al.  Increased Plasma Levels of Brain Natriuretic Peptide in Patients With Acute Myocardial Infarction , 1993, Circulation.

[23]  M. Freed,et al.  Special Report Diagnosis and Therapy of Kawasaki Disease in Children , 1993, Circulation.

[24]  Y. Sasaguri,et al.  Immunopathology and cytokine detection in the skin lesions of patients with Kawasaki disease. , 1993, The Journal of pediatrics.

[25]  H. Imura,et al.  Increased human brain natriuretic peptide in congestive heart failure. , 1990, The New England journal of medicine.

[26]  P. Pelkonen,et al.  Circulating interleukin-1 beta in patients with Kawasaki disease. , 1988, The New England journal of medicine.

[27]  Hal B. Jenson,et al.  Nelson Textbook of Pediatrics , 1965 .